HEALTH OF WOMAN. 2020.4(150): 14–17; doi 10.15574/HW.2020.150.14
Pyrohova V. I. , Nehrych O. I.
Lviv national medical University named Danylo Galitsky

The use of a reliable safe method of contraception is important for women with multiple sclerosis. Proper and systematic use of reliable methods of contraception should be followed to avoid the need for abortion or the risk of giving birth to a child with developmental disabilities. At the same time, the use of contraception in women with MS has certain features, which determines the importance of studying the problem.
The objective: to investigate the use of drugs to prevent unwanted pregnancies among women with multiple sclerosis.
Materials and methods. The level of use of various contraceptive methods in women with multiple sclerosis and features of contraception in this category of patients are analyzed.
Results. 35.3% of women with MS use contraceptive methods. The most common method is barrier (condoms) – 32.8%. With age, the frequency of contraceptive use in women with MS decreases and in the age group of 39–49 years, the vast majority of women (85.7%) do not use any methods of contraception.
Conclusions. The critically low level of contraceptive use among women with MS increases the risk of adverse effects, including the birth of a sick child or the deterioration of a woman’s condition due to abortion. An informed choice of contraceptives is important in providing quality comprehensive care.
Keywords: contraception, multiple sclerosis.

REFERENCES

1. Bove R and Chitnis T. 2014. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler 20:520-526. https://doi.org/10.1177/1352458513519181; PMid:24561324

2. Coyle PK. 2016. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord 9:198-210. https://doi.org/10.1177/1756285616631897; PMid:27134675 PMCid:PMC4811012

3. Alwan S, Yee IM, Dybalski M et al. 2013. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 19:351-358. https://doi.org/10.1177/1352458512452920; PMid:22760102

4. Hellwig K. 2014. Pregnancy in multiple sclerosis. Eur Neurol 72(Suppl. 1):39-42. https://doi.org/10.1159/000367640; PMid:25278125

5. Sahin L, Nallani SC and Tassinari MS. 2016. Medication use in pregnancy and the pregnancy and lactation labeling rule. Clin Pharmacol Ther 100:23-25. https://doi.org/10.1002/cpt.380; PMid:27082701

6. Houtchens M, Zapata L, Curtis K, Whiteman M. 2017. Contraception for women with multiple sclerosis: Guidance for healthcare providers. Multiple Sclerosis Journal 23(6):757-764. https://doi.org/10.1177/1352458517701314; PMid:28338393 PMCid:PMC5785786

7. Curtis KM, Tepper NK, Jatlaoui TC et al. 2016. U.S. medical eligibility criteria for contraceptive use. MMWR Recomm Rep (65):1-103. https://doi.org/10.15585/mmwr.rr6503a1

8. McCombe PA and Greer JM. 2013. Female reproductive issues in multiple sclerosis. Mult Scler 19:392-402. https://doi.org/10.1177/1352458512452331; PMid:22733837

9. Zapata LB, Oduyebo T, Whiteman MK et al. 2016. Contraceptive use among women with multiple sclerosis: A systematic review. Contraception 94:612-620. https://doi.org/10.1016/j.contraception.2016.07.013; PMid:27452316 PMCid:PMC6579526

10. World Health Organization. Selected practice recommendations for contraceptive use. 3rd ed. Geneva, World Health Organization. 2016.

11. Gavin L, Moskosky S, Carter M et al. 2014. Providing quality family planning services: Recommendations of CDC and the U.S. Office of Population Affairs. MMWR Recomm Rep 63:1-54.